Investor Relations
Stay informed with the latest updates, reports, and financial insights from Boule.
Improving health for everyone, everywhere
Boule develops, manufactures and commercializes diagnostic instruments and consumables for healthcare providers worldwide. Boule operates via subsidiaries in Sweden, the USA, Mexico and Russia.
The company products are sold globally primarily through more than 200 distributors and partners in more than 100 countries, supported by Boule’s own local sales and support personnel.
The Boule shares are listed on Nasdaq Stockholm since 2011.
Highlights from Our Latest Results
558 MSEK
Net Sales
64 MSEK
Operating Profit
45 %
Gross Margin
47 MSEK
Operating Cash Flow
Strategic Focus Areas
- Long term growth in sales above 10 percent per year
- Operating margin (EBIT-margin) above 15 percent
- Net debt (interest bearing debts minus cash and cash equivalents) no greater than three times operating profit (EBIT) on an annualized basis
- The annual dividend should correspond to 25-50 percent of profit for the period, after due consideration of company liquidity
Key Figures Over Time
Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million.
Contact Us
If you have any questions regarding Boule´s business or investor relations, do not hesitate to contact Holger Lembrér, CFO or use the below form.
To subscribe to press releases and reports via email click here.